COVID-19 vaccine from Anhui earns conditional approval
By Wang Xiaoyu |
chinadaily.com.cn |
Updated: 2022-03-02 17:20
Share
Share - WeChat
China has given conditional approval for a recombinant protein subunit COVID-19 vaccine developed by domestic company Anhui Zhifei Longcom Biopharmaceutical, the National Medical Products Administration said on Wednesday.
The vaccine uses purified pieces of the virus' protein to trigger an immune response. It is the first vaccine based on this technology to be approved by the top drug regulator.
In total, five COVID-19 vaccines have been approved for public use in China so far.
- China reports over 50% surge in visa-free foreigner entries in first 8 months
- China's defense minister pledges greater efforts to safeguard world peace at Beijing Xiangshan Forum
- China commemorates start of war against Japanese aggression
- China steps up preservation of Flying Tigers relics
- Jilin rice-crab farming system improves saline-alkali land
- Senior CPC official stresses study of fifth volume of 'Xi Jinping: The Governance of China'
